Researchers in the United States have launched a pilot study testing GLP-1 drugs as once‑weekly weight‑loss injections for cats, the study team said.

https://www.instagram.com/p/CXsBdQmLdv2/

The study, named MEOW-1, aims to evaluate whether the class of drugs now used for human weight loss can help manage overweight and diabetic cats — a growing veterinary concern. In the United Kingdom there are an estimated 54,500 cats with diabetes, underscoring the scale of metabolic disease in companion animals.

MEOW-1 will enroll client‑owned cats to assess whether GLP-1 therapy can reduce weight and support metabolic health. The study team described the effort as a response to the limited tools veterinarians currently have for sustained feline weight management and metabolic control.

“Obesity remains the biggest preventable health problem facing our pets today,” researchers said, framing the trial as part of efforts to reduce the burden of obesity and its complications in cats.

Many overweight cats already receive insulin injections to manage diabetes, and the MEOW-1 investigators hope the GLP-1 approach can offer an additional tool for clinicians. The trial’s design will focus on once‑weekly dosing and monitoring of weight and associated health measures in enrolled animals.

Vivid descriptions from commentators on pet body condition contrast a desired sylph‑like appearance with the reality of plump, cuddly pets whose life spans may be shortened by excess weight. Supporters of the trial say a safe, effective medical option could shift the balance in favor of longer, healthier lives for cats.

MEOW-1 is being conducted in the United States; reporting on the pilot study appears alongside broader analysis of GLP-1 use in pets in outlets such as The New York Times.

The research team says the study is intended to clarify whether GLP-1 therapy is both safe and practical for use in household cats, and whether it can be integrated with standard diabetes care, including insulin when needed. The trial’s focus on client‑owned animals reflects an effort to measure outcomes in typical home settings rather than laboratory conditions.

Veterinary observers point to the practical challenges of feline weight loss in real life, where dietary changes and activity adjustments can be difficult to sustain. MEOW-1 aims to measure whether a pharmacological approach can produce meaningful weight reduction that translates to better clinical outcomes for cats with or at risk of diabetes.

The trial’s launch has prompted discussion among clinicians and cat owners about the role of medical therapies alongside diet and lifestyle interventions. Advocates stress that any new therapy must demonstrate both safety and improvements in quality and length of life for patients.

For now, MEOW-1 represents an early test of translating human obesity treatments into veterinary practice. The study name — MEOW-1 — marks the first formal clinical evaluation specifically targeting weight loss with GLP-1 drugs in cats, according to the research description.

Source

Original reporting: view the original article.